scholarly journals Valiolamine, a new .ALPHA.-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus.

1984 ◽  
Vol 37 (11) ◽  
pp. 1301-1307 ◽  
Author(s):  
YUKIHIKO KAMEDA ◽  
NAOKI ASANO ◽  
MICHIYO YOSHIKAWA ◽  
MASAYOSHI TAKEUCHI ◽  
TAKUJI YAMAGUCHI ◽  
...  
Keyword(s):  
Streptomyces Hygroscopicus ◽  
Alpha Glucosidase

TOTAL POLYPHENOL CONTENT, FREE RADICAL SCAVENGING, ALPHA-GLUCOSIDASE INHIBITION CAPACITY, THE EFFICACY IN CONTROLLING BLOOD GLUCOSE OF DIABETIC RATS OF THE MIXTURE VOS EXTRACTED FROM THE LEAVES OF CLEISTOCALYX OPERCULATUS, PSIDIUM GUAJAVA AND NELUMBO NUCIFERA

2013 ◽  
pp. 50-55
Author(s):  
Tuyet Mai Truong ◽  
Thi Lam Nguyen ◽  
Lan Anh Pham ◽  
Hoang Kien Truong
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Radical Scavenging ◽  
Psidium Guajava ◽  
Free Radical Scavenging ◽  
Diabetic Mice ◽  
Cleistocalyx Operculatus ◽  
Prevention And Treatment ◽  
Treatment Of Diabetes ◽  
Alpha Glucosidase

Objective: Plant polyphenols have antioxidant capacity and alpha-glucosidase inhibition to supporting for prevention and treatment of diabetes. Materials and Method: Present study was conducted to determine the content of total polyphenols, free radical scavenging and alpha-glucosidase inhibition of the VOS mixture that extracted from leaves (Voi leaves - Cleistocalyx operculatus (V), Oi leaves - Psidium guajava (O), Sen leaves - Nelumbo nucifera (S)). Results: The efficacy of blood glucose controlling in diabetic mice was investigated. After 8 weeks of administration with 200 mg VOS/kg body weight and 400 mg VOS/kg body weight, VOS diabetic mice had significantly reduced blood glucose level as compared to control diabetic mice. VOS diabetic mice with 400 mg dosage are lower in blood glucose levels than that of the diabetic mice with 200 mg. Also, the significant reducing in HbA1c was observed in VOS diabetic mice as compared with control diabetic mice. Conclusion: VOS-product extracted from Cleistocalyx operculatus leaves, guava leaves, lotus leaves might be considered as a safe product and to be a potential product in the supporting of prevention and treatment of diabetes.

Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update

2019 ◽  
Vol 25 (23) ◽  
pp. 2510-2525 ◽  
Author(s):  
Bashir Usman ◽  
Neha Sharma ◽  
Saurabh Satija ◽  
Meenu Mehta ◽  
Manish Vyas ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Patient Compliance ◽  
Postprandial Hyperglycemia ◽  
Diabetic Patients ◽  
Poor Patient ◽  
Glucosidase Inhibitors ◽  
Poor Patient Compliance ◽  
Recent Developments ◽  
Alpha Glucosidase

The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for the management of type 2 diabetes but were having certain limitations of their safety. Alphaglucosidase is a family of enzyme originated from the pancreas which plays a role in the anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results in frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and the formation of glycated end products. Alphaglucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, such as poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.

Sign in / Sign up

Export Citation Format

Share Document